PharmAust Limited (PAA.AX)

0.0830 +0.0010 (+1.22%) As of 10:24AM AEDT. Market open.

PharmAust Limited

5/3 Brodie Hall Drive
Bentley, WA 6102
Australia
61 8 9202 6814
https://www.pharmaust.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.	Exec. Chairman & Acting CEO	286k	N/A	1956
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD	Fin. Director, Company Sec. & Non-Exec. Director	138k	N/A	1978
Mr. Robert Charles Bishop LLB (Hons)	Exec. Director	140.8k	N/A	N/A
Ms. Fiona Milner	Gen. Mang. of Epichem Pty Ltd	N/A	N/A	N/A
Dr. Gary Pitt	Head of Chemistry	N/A	N/A	N/A
Dr. James Rixson	Head of Production	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

Corporate governance

PharmAust Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.